Webster Equity Partners has agreed to acquire Lifecore Biomedical in a deal valued at up to $663.7 million. Lifecore (Nasdaq: LFCR), founded in 1965 and based in Chaska, Minnesota, is a contract development and manufacturing organization specializing in sterile injectable pharmaceuticals and injectable-grade hyaluronic acid. Webster, a middle market private equity firm based in Waltham, Massachusetts, focuses exclusively on healthcare and typically targets businesses with revenue between $20 million and $200 million.
The firm’s practice areas include physician practice management, post-acute care, women’s and children’s health, behavioral health, and pharma services. The transaction is expected to close at the end of the fourth quarter of 2026, after which Lifecore’s common stock will be delisted from the Nasdaq stock market.
Source: Healthcare Investor · Summarized by HeadlinesBriefing